Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Remacemide
General information
Remacemide hydrochloride is a low-affinity, non-competitive N-methyl- d -aspartate (NMDA) receptor blocker that has been used in epilepsy, Parkinson's disease, Huntington's chorea [ ], and neuroprotection after stroke [ ]. Its pharmacology, clinical pharmacology, uses, and adverse reactions and interactions have been reviewed [ , ]. However, there appear to be no current clinical studies of this drug and there have been no publications on it since about 2009.
Drug studies
Observational studies
Adverse reactions to remacemide were studied in 40 patients with refractory epilepsy randomized to placebo or ascending weekly doses of remacemide in a twice or four times a day regimen for up to 1 month [ ]. There were adverse events in 38 patients, most commonly dizziness, abdominal pain, headache, diplopia, fatigue, dyspepsia, and abnormal vision.
The efficacy of adjunctive therapy with remacemide was evaluated in 11 children [ ]. Remacemide was well tolerated in doses up to 13.5 mg/kg/day. The most common adverse events were dizziness, ataxia, and gastrointestinal events. One patient died after a suspected seizure, which was unlikely to have been related to remacemide.
You're Reading a Preview
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here